Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches
| Autor: | J.R. van Sornsen de Koste, Suresh Senan, Berend J. Slotman, H. Tekatli, Femke O.B. Spoelstra, Miguel A. Palacios |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Organs at Risk
Pulmonary and Respiratory Medicine Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Planning target volume Dose distribution Radiosurgery SABR volatility model 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Ablative case medicine High doses Humans Stage (cooking) Neoplasm Staging Lung business.industry Radiotherapy Dosage Radiation therapy Editorial Commentary Treatment Outcome medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Radiology business Radiotherapy Image-Guided |
| Zdroj: | Tekatli, H, Spoelstra, F O B, Palacios, M, van Sornsen de Koste, J, Slotman, B J & Senan, S 2018, ' Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors : New insights and approaches ', Lung Cancer, vol. 123, pp. 142-148 . https://doi.org/10.1016/j.lungcan.2018.07.002 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2018.07.002 |
| Popis: | The use of stereotactic ablative radiotherapy (SABR) for central lung tumors is increasing. Centrally located lung tumors can be subdivided into two categories, namely the ‘moderately central’ tumors where the planning target volume is located within 2 cm of the proximal bronchial tree, and the ‘ultracentral’ tumors where a planning target volume (PTV) overlaps the trachea or main stem bronchi. The toxicity of SABR appears acceptable when ‘moderately central’ tumors are treated using techniques that comply with organs at risk tolerance doses used for prospective trials and in recent publications. A high toxicity is seen when ultracentral tumors are treated using SABR, and conventional radiotherapy appears more appropriate in such tumors as the true normal organ tolerance doses remain unknown. When ultracentral tumors are treated with non-SABR hypofractionated radiotherapy, a homogenous dose distribution in the planning target volume and limitation of both normal organ maximum point doses and volumes receiving high doses seems to be needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect